The rapid evolution of treatment strategies for hepatitis C. (Q38204657)

31 August 2017

title

The rapid evolution of treatment strategies for hepatitis C. (English)

1 reference

31 August 2017

1 reference

Andrew J Muir

1

1 reference

31 August 2017

language of work or name

English

0 references

publication date

15 April 2014

1 reference

The American Journal of Gastroenterology

31 August 2017

published in

1 reference

31 August 2017

volume

109

1 reference

31 August 2017

issue

5

1 reference

31 August 2017

page(s)

628-35; quiz 636

1 reference

Sofosbuvir for previously untreated chronic hepatitis C infection

31 August 2017

cites work

1 reference

https://api.crossref.org/works/10.1038%2FAJG.2014.66

Diagnosis, management, and treatment of hepatitis C: an update

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FAJG.2014.66

Boceprevir versus placebo with pegylated interferon alfa-2b and ribavirin for treatment of hepatitis C virus genotype 1 in patients with HIV: a randomised, double-blind, controlled phase 2 trial.

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FAJG.2014.66

Hepatitis C virus infection-related morbidity and mortality among patients with human immunodeficiency virus infection

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FAJG.2014.66

HIV, age, and the severity of hepatitis C virus-related liver disease: a cohort study

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FAJG.2014.66

The changing epidemiology of hepatitis C virus infection in the United States: National Health and Nutrition Examination Survey 2001 through 2010.

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FAJG.2014.66

Simeprevir increases rate of sustained virologic response among treatment-experienced patients with HCV genotype-1 infection: a phase IIb trial

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FAJG.2014.66

Sofosbuvir and ribavirin for hepatitis C genotype 1 in patients with unfavorable treatment characteristics: a randomized clinical trial

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FAJG.2014.66

Daclatasvir plus sofosbuvir for previously treated or untreated chronic HCV infection

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FAJG.2014.66

Sofosbuvir for hepatitis C genotype 2 or 3 in patients without treatment options

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FAJG.2014.66

Concordance between sustained virologic response week 12 (SVR12) and SVR24 in genotype 1 hepatitis C virus patients receiving interferon-free treatment in the SOUND-C2 study

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FAJG.2014.66

miR-133a mediates TGF-β-dependent derepression of collagen synthesis in hepatic stellate cells during liver fibrosis

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FAJG.2014.66

The prevalence of hepatitis C virus infection in the United States, 1999 through 2002

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FAJG.2014.66

Insurance status and treatment candidacy of hepatitis C patients: analysis of population-based data from the United States

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FAJG.2014.66

21 January 2018

Identifiers

DOI

10.1038/AJG.2014.66

1 reference

release_lfcp2c2qlba5xewjlit3xcjj2a

31 August 2017

Fatcat ID

1 reference

Fatcat

https://api.fatcat.wiki/v0/release/lfcp2c2qlba5xewjlit3xcjj2a

mapped directly with Wikidata item

24 November 2022

based on heuristic

1 reference